Turk J Pharm Sci. 2024 Mar 25;21(1):81-86. doi: 10.4274/tjps.galenos.2023.87450.
ABSTRACT
OBJECTIVES: This study investigated the impact of a high-fat diet streptozotocin (STZ)-induced diabetes and dapagliflozin treatment on hepatic protein expression of CYP3A4.
MATERIALS AND METHODS: In our study, 34 male Sprague-Dawley rats were randomly divided into four groups: Control, high-fat diet and STZ-induced diabetes, dapagliflozin-treated control, and dapagliflozin-treated diabetes. In the microsomes obtained from the livers of these rats, the protein expression levels of CYP3A4 were determined by Western blotting.
RESULTS: Hepatic CYP3A4 protein expression levels in the control group treated with dapagliflozin were significantly decreased compared with those in the control group. In addition, hepatic CYP3A4 protein expression levels were decreased in dapagliflozin-treated diabetic Sprague-Dawley rats compared with those in both control and diabetic group rats, but the difference between the groups was not statistically significant.
CONCLUSION: According to these two results, the use of dapagliflozin inhibited hepatic CYP3A4 protein expression.
PMID:38529568 | DOI:10.4274/tjps.galenos.2023.87450
